EsoGuard Testing now incorporated in
Texas-based Ancira Auto Group's
corporate Health and Wellness Program
NEW
YORK, Aug. 24, 2023 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company") a commercial-stage, cancer prevention medical
diagnostics company and majority-owned subsidiary of PAVmed Inc.
(Nasdaq: PAVM, PAVMZ), announced that the Company has contracted
with the Ancira Auto Group ("Ancira"), a premier auto dealer
serving South Texas, to offer
EsoGuard® esophageal precancer testing to eligible
employees across all twelve of its locations in San Antonio and surrounding areas. This
represents Lucid's first such employer contract as part of a direct
contracting strategic initiative it launched earlier this year.
Lucid is expanding its commercial team to include a dedicated
full-time head of employer relations, who will spearhead this
important direct contracting strategic initiative.
"Lucid is deeply committed to seeking creative ways to expand
patient access to EsoGuard esophageal precancer testing across
multiple commercial channels, with the goal of preventing
esophageal cancer and cancer deaths," said Shaun O'Neil, Lucid's Executive Vice President
& Chief Operating Officer. "We believe we can replicate the
success of other early cancer detection companies who have
supplemented traditional commercial channels by partnering with
employers and other self-insured entities to offer early detection
testing as an employee or member benefit. We commend Ancira for
their commitment to their employees' long-term health through a
robust Health & Wellness Program, and for embracing EsoGuard
precancer testing as a cost-effective approach to detect, monitor,
and treat a precancer before it develops into a highly lethal
cancer. We look forward to offering EsoGuard testing to all at-risk
Ancira employees through dedicated on-site #CheckYourFoodTube
Precancer Testing events in the coming weeks. We expect this to
serve as a model for future contractual engagements with employers,
unions, and other self-insured entities, which we believe will
supplement the strong commercial progress we are making through
more traditional payor pathways."
Pursuant to this three-year contract at a negotiated
per-employee rate, Lucid will partner with local physicians to
identify Ancira employees who meet professional society guidelines
for esophageal precancer testing and perform EsoCheck®
cell collection at Ancira locations across the San Antonio metropolitan area. EsoGuard
analysis of the samples will then be performed at Lucid's
CLIA-certified laboratory in Lake Forest,
California. Based on the EsoGuard result, the physician will
recommend further monitoring or treatment as indicated by these
guidelines.
"We are very excited about teaming up with Lucid Diagnostics
and, importantly, making the EsoGuard test available to our
employees", said April Ancira, Vice
President of Ancira Auto Group. "Ancira is deeply committed to our
employee's health and safety, which includes cancer awareness and
prevention. By providing this important esophageal precancer test
to eligible employees, we intend to accomplish both as we continue
to strive to provide Ancira employees with the resources they need
to maintain a healthy life and wellbeing."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on
the millions of patients with gastroesophageal reflux disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device - the first
and only commercially available tools designed with the goal of
preventing cancer and cancer deaths through widespread, early
detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-executes-first-direct-employer-contract-to-provide-esoguard-esophageal-precancer-testing-as-an-employee-benefit-301908954.html
SOURCE Lucid Diagnostics